P2RY12 and chronic kidney disease: Summing up, DAPT with potent P2Y12 inhibitors may be a plausible treatment option for CKD patients, but further controlled studies on the impact of duration and type of DAPT, along with disease-related factors on ischemic and bleeding outcomes, in CKD patients are warranted.